← Back to Screener
Protara Therapeutics, Inc. Common Stock (TARA)
Price$4.16
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-51.56%
Price vs S&P 500 (4W)-21.05%
VGM Score36.50
Market Capitalization$233.81M
All Metrics
Book Value / Share (Quarterly)$3.29
P/TBV (Annual)0.13x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.15
Price vs S&P 500 (YTD)-30.11%
EPS (TTM)$-1.35
10-Day Avg Trading Volume0.65M
EPS Excl Extra (TTM)$-1.35
EPS (Annual)$-1.34
ROI (Annual)-29.24%
Cash / Share (Quarterly)$2.47
ROA (Last FY)-27.42%
EBITD / Share (TTM)$-1.48
ROE (5Y Avg)-41.77%
Cash Flow / Share (Annual)$-1.05
P/B Ratio1.29x
P/B Ratio (Quarterly)1.55x
Net Income / Employee (Annual)$-1,248,700
Net Interest Coverage (TTM)-3.02x
ROA (TTM)-36.02%
EPS Incl Extra (Annual)$-1.34
Current Ratio (Annual)14.58x
Quick Ratio (Quarterly)15.39x
3-Month Avg Trading Volume0.88M
52-Week Price Return33.33%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.77
P/S Ratio (Annual)79.26x
Asset Turnover (Annual)0.03x
52-Week High$7.82
EPS Excl Extra (Annual)$-1.34
CapEx CAGR (5Y)-36.07%
Tangible BV CAGR (5Y)24.06%
26-Week Price Return-43.63%
Quick Ratio (Annual)14.34x
13-Week Price Return-28.52%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)15.69x
Enterprise Value$219.07M
Book Value / Share Growth (5Y)-27.09%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-113.22%
Cash / Share (Annual)$2.90
3-Month Return Std Dev55.76%
Net Income / Employee (TTM)$-1,376,200
ROE (Last FY)-29.24%
Net Interest Coverage (Annual)-4.75x
EPS Basic Excl Extra (Annual)$-1.34
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.35
ROI (TTM)-38.70%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$9.06
Price vs S&P 500 (52W)8.97%
Year-to-Date Return-21.95%
5-Day Price Return-7.96%
EPS Normalized (Annual)$-1.34
ROA (5Y Avg)-37.76%
Net Profit Margin (Annual)-113.22%
Month-to-Date Return-10.54%
Cash Flow / Share (TTM)$-6.09
EBITD / Share (Annual)$-1.50
Operating Margin (Annual)-256.95%
ROI (5Y Avg)-41.77%
EPS Basic Excl Extra (TTM)$-1.35
P/TBV (Quarterly)0.18x
P/B Ratio (Annual)1.40x
Book Value / Share (Annual)$3.67
Price vs S&P 500 (13W)-36.78%
Beta1.51x
Revenue / Share (TTM)$0.00
ROE (TTM)-38.70%
52-Week Low$2.77
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.31est. -0.38
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.15
4.14
4.14
4.14
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TARAProtara Therapeutics, Inc. Common Stock | — | — | D | $4.16 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Protara Therapeutics develops transformative therapies for cancer and rare diseases with limited treatment options. The pipeline includes TARA-002 for lymphatic malformations and intravenous choline chloride for intestinal failure-associated liver disease (IFALD). The company focuses on underserved patient populations with significant unmet medical needs.